APEN
Apollo Endosurgery, Inc. [APEN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
APEN Stock Summary
Top 10 Correlated ETFs
APEN
Top 10 Correlated Stocks
APEN
In the News
Buy-rated Boston Scientific's $615 million takeover of Apollo Endosurgery is a positive, says Needham
Boston Scientific Corp.'s BSX, +0.88% $615 million acquisition of Apollo Endosurgery Inc. APEN, +65.50% announced earlier is complementary to the former's endoscopy franchise, as it leverages its gastroenterologist call point while offering the potential for it to expand into surgical endoscopy and bariatric surgery, Needham analysts aid Tuesday. The deal is expected to have no material impact on Boston Scientific's 2023 per-share earnings but to boost it after that.
Apollo Endosurgery Stock Soars on Buyout Buzz
Apollo Endosurgery Inc (NASDAQ:APEN) stock is soaring, up 63.4% at $9.80 at last glance, after news that Boston Scientific Corp (BSX) will acquire the medical equipment name for $417 million.
Boston Scientific to acquire Apollo Endosurgery for $615 million in cash
Boston Scientific Corp. BSX, -0.82% said Tuesday it has agreed to acquire Apollo Endosurgery Inc. APEN, for $10 a share, or about $615 million in cash. The news sent Apollo's stock, which closed Monday at $6, up 61% in premarket trade.
Apollo Endosurgery, Inc. (APEN) Q3 2022 Earnings Call Transcript
Apollo Endosurgery, Inc. (NASDAQ:APEN ) Q3 2022 Earnings Conference Call November 1, 2022 4:30 PM ET Company Participants Matt Kreps – Investor Relations Chas McKhann – Chief Executive Officer Jeff Black – Chief Financial Officer Conference Call Participants Mathew Blackman – Stifel Matt Hewitt – Craig-Hallum Capital Frank Takkinen – Lake Street Capital Josh Jennings – Cowen Simran Kaur – Piper Sandler Operator Good afternoon, ladies and gentlemen. And welcome to the Apollo Endosurgery Third Quarter 2022 Results Call.
Apollo Endosurgery to Report Third Quarter Results on November 1, 2022
AUSTIN, TX / ACCESSWIRE / October 18, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the third quarter ended September 30, 2022 on Tuesday, November 1, 2022, after market close. In conjunction with the release, Apollo will host a live webcast audio call with presentation slides at 3:30 p.m.
Apollo Endosurgery, Inc. (APEN) CEO Chas McKhann on Q2 2022 Results - Earnings Call Transcript
Apollo Endosurgery, Inc. (NASDAQ:APEN ) Q2 2022 Earnings Conference Call August 2, 2022 4:30 PM ET Company Participants Matt Kreps - Investor Relations Chas McKhann - Chief Executive Officer Jeff Black - Chief Financial Officer Conference Call Participants Chris Cooley - Stephens Simran Kaur - Piper Sandler Frank Takkinen - Lake Street Capital Matt Hewitt - Craig-Hallum Capital Operator Good afternoon, ladies and gentlemen and welcome to Apollo Endosurgery Second Quarter 2022 Results. At this time all participants have been placed on a listen-only mode and we will open the floor for your questions and comments after the presentation.
Apollo Endosurgery: Collect Shares At A Discount Following Q2 Earnings
Apollo Endosurgery came in with another strong quarter of top-line growth whilst growing gross margins on the same. The company saw substantial growth in each of its key segments, coupled with regulatory momentum in its Apollo ESG and REVISE series.
Apollo Endosurgery to Report Second Quarter Results on August 2, 2022
AUSTIN, TX / ACCESSWIRE / July 21, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the second quarter ended June 30, 2022 on Tuesday, August 2, 2022, after market close. In conjunction with the release, Apollo will host a live webcast audio call with presentation slides at 3:30 p.m.
Hot Penny Stocks to Watch Right Now? 3 For Your July List
Which penny stocks are you watching right now? The post Hot Penny Stocks to Watch Right Now?
Apollo Endosurgery's New Obesity Endoscopic Systems Receive FDA Nod
Apollo Endosurgery Inc (NASDAQ: APEN) announced the marketing authorization of the Apollo ESG, Apollo ESG Sx, Apollo REVISE, and Apollo REVISE Sx Systems through the FDA De Novo Classification process. The process is a premarket review pathway for low-to moderate-risk devices.
APEN Financial details
APEN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 4.74 | 3.08 | 2.35 | 1.85 | 2.08 | |
| Net income per share | -2.01 | -2.31 | -1.27 | -0.99 | -0.82 | |
| Operating cash flow per share | -0.98 | -1.17 | -1.19 | -0.91 | -0.48 | |
| Free cash flow per share | -1.14 | -1.31 | -1.23 | -0.94 | -0.53 | |
| Cash per share | 2.25 | 1.21 | 1.39 | 1.59 | 3 | |
| Book value per share | 3.68 | 1.46 | 0.1 | 0.3 | 2.02 | |
| Tangible book value per share | 0.49 | 0.69 | -0.51 | -0.2 | 1.7 | |
| Share holders equity per share | 3.68 | 1.46 | 0.1 | 0.3 | 2.02 | |
| Interest debt per share | 2.79 | 1.28 | 2.69 | 2.77 | 2.05 | |
| Market cap | 75.97M | 68.28M | 61.4M | 77.37M | 254.95M | |
| Enterprise value | 78.78M | 65.47M | 85.43M | 99.03M | 217.83M | |
| P/E ratio | -2.78 | -1.49 | -2.24 | -3.42 | -10.33 | |
| Price to sales ratio | 1.18 | 1.12 | 1.21 | 1.84 | 4.05 | |
| POCF ratio | -5.7 | -2.95 | -2.4 | -3.72 | -17.64 | |
| PFCF ratio | -4.91 | -2.63 | -2.31 | -3.61 | -16.02 | |
| P/B Ratio | 1.52 | 2.37 | 28.92 | 11.46 | 4.16 | |
| PTB ratio | 1.52 | 2.37 | 28.92 | 11.46 | 4.16 | |
| EV to sales | 1.22 | 1.08 | 1.68 | 2.36 | 3.46 | |
| Enterprise value over EBITDA | -6.17 | -2.03 | -4.49 | -7.34 | -16.79 | |
| EV to operating cash flow | -5.91 | -2.83 | -3.33 | -4.76 | -15.07 | |
| EV to free cash flow | -5.1 | -2.52 | -3.21 | -4.62 | -13.69 | |
| Earnings yield | -0.36 | -0.67 | -0.45 | -0.29 | -0.1 | |
| Free cash flow yield | -0.2 | -0.38 | -0.43 | -0.28 | -0.06 | |
| Debt to equity | 1.19 | 1.58 | 34.13 | 10.47 | 1.15 | |
| Debt to assets | 0.54 | 0.61 | 0.97 | 0.91 | 0.53 | |
| Net debt to EBITDA | -0.22 | 0.09 | -1.26 | -1.61 | 2.86 | |
| Current ratio | 2.23 | 1.97 | 0.97 | 5.02 | 7.92 | |
| Interest coverage | -4.98 | -9.87 | -5.8 | -3.01 | -2.31 | |
| Income quality | 0.49 | 0.5 | 0.93 | 0.92 | 0.59 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.21 | 0.22 | 0.27 | 0.26 | 0.29 | |
| Research and developement to revenue | 0.13 | 0.2 | 0.2 | 0.18 | 0.15 | |
| Intangibles to total assets | 0.4 | 0.2 | 0.18 | 0.15 | 0.07 | |
| Capex to operating cash flow | 0.16 | 0.12 | 0.04 | 0.03 | 0.1 | |
| Capex to revenue | -0.03 | -0.05 | -0.02 | -0.01 | -0.02 | |
| Capex to depreciation | -0.22 | -0.31 | -0.24 | -0.17 | -0.45 | |
| Stock based compensation to revenue | 0.01 | 0.02 | 0.03 | 0.05 | 0.1 | |
| Graham number | 12.91 | 8.71 | 1.68 | 2.58 | 6.1 | |
| ROIC | -0.76 | -3.6 | -4.88 | -12.3 | 0.35 | |
| Return on tangible assets | -0.41 | -0.77 | -0.45 | -0.34 | -0.2 | |
| Graham Net | -0.93 | -0.41 | -1.45 | -1.02 | 1.12 | |
| Working capital | 31.77M | 23.67M | -1.79M | 46.86M | 100.21M | |
| Tangible asset value | 6.66M | 13.68M | -11M | -4.56M | 51.55M | |
| Net current asset value | -1.55M | 2.48M | -21.46M | -12.16M | 44.41M | |
| Invested capital | 0.67 | 0.73 | 25.41 | 8.58 | 0.87 | |
| Average receivables | 11.12M | 11.56M | 10.31M | 8.73M | 9.15M | |
| Average payables | 11.74M | 16.81M | 12.6M | 6.79M | 4.13M | |
| Average inventory | 13.25M | 12.14M | 9.4M | 9.59M | 11.14M | |
| Days sales outstanding | 66.57 | 68.32 | 66.45 | 71.34 | 58.4 | |
| Days payables outstanding | 272.17 | 201.79 | 144.35 | 67.73 | 59.69 | |
| Days of inventory on hand | 213 | 131.06 | 129.23 | 189.93 | 155.82 | |
| Receivables turnover | 5.48 | 5.34 | 5.49 | 5.12 | 6.25 | |
| Payables turnover | 1.34 | 1.81 | 2.53 | 5.39 | 6.11 | |
| Inventory turnover | 1.71 | 2.78 | 2.82 | 1.92 | 2.34 | |
| ROE | -0.55 | -1.59 | -12.92 | -3.35 | -0.4 | |
| Capex per share | -0.16 | -0.15 | -0.05 | -0.03 | -0.05 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.56 | 0.42 | 0.42 | 0.48 | 0.48 | |
| Net income per share | -0.23 | -0.27 | -0.21 | -0.26 | -0.28 | |
| Operating cash flow per share | -0.13 | -0.11 | -0.22 | -0.15 | -0.15 | |
| Free cash flow per share | -0.14 | -0.13 | -0.23 | -0.16 | -0.18 | |
| Cash per share | 0.94 | 2.37 | 2.06 | 1.85 | 1.64 | |
| Book value per share | 0 | 1.6 | 1.39 | 1.19 | 1.04 | |
| Tangible book value per share | -0.35 | 1.35 | 1.15 | 0.97 | 0.82 | |
| Share holders equity per share | 0 | 1.6 | 1.39 | 1.19 | 1.04 | |
| Interest debt per share | 1.97 | 1.51 | 1.39 | 1.36 | 1.35 | |
| Market cap | 262.93M | 322.52M | 239.9M | 147.31M | 225.07M | |
| Enterprise value | 291.46M | 285.4M | 211.9M | 126.39M | 212.26M | |
| P/E ratio | -9.87 | -7.75 | -7.13 | -3.53 | -4.92 | |
| Price to sales ratio | 16.08 | 19.94 | 14.4 | 7.63 | 11.5 | |
| POCF ratio | -70.95 | -74.33 | -27.61 | -24.25 | -36.33 | |
| PFCF ratio | -65.91 | -66.72 | -25.96 | -22.22 | -30.74 | |
| P/B Ratio | -2.86K | 5.27 | 4.36 | 3.06 | 5.32 | |
| PTB ratio | -2.86K | 5.27 | 4.36 | 3.06 | 5.32 | |
| EV to sales | 17.83 | 17.65 | 12.72 | 6.55 | 10.84 | |
| Enterprise value over EBITDA | -65.16 | -52.55 | -33.83 | -14.99 | -22.7 | |
| EV to operating cash flow | -78.65 | -65.78 | -24.39 | -20.81 | -34.26 | |
| EV to free cash flow | -73.07 | -59.04 | -22.93 | -19.06 | -28.99 | |
| Earnings yield | -0.03 | -0.03 | -0.04 | -0.07 | -0.05 | |
| Free cash flow yield | -0.02 | -0.01 | -0.04 | -0.05 | -0.03 | |
| Debt to equity | -773.63 | 1.15 | 1.27 | 1.51 | 1.74 | |
| Debt to assets | 1 | 0.53 | 0.56 | 0.6 | 0.64 | |
| Net debt to EBITDA | -6.38 | 6.83 | 4.47 | 2.48 | 1.37 | |
| Current ratio | 3.62 | 7.92 | 7.78 | 6.37 | 6 | |
| Interest coverage | -3.36 | -1.33 | -5.93 | -5.45 | -5.45 | |
| Income quality | 0.56 | 0.42 | 1.03 | 0.58 | 0.54 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.28 | 0.28 | 0.31 | 0.26 | 0.27 | |
| Research and developement to revenue | 0.16 | 0.15 | 0.16 | 0.15 | 0.14 | |
| Intangibles to total assets | 0.14 | 0.07 | 0.07 | 0.07 | 0.07 | |
| Capex to operating cash flow | 0.08 | 0.11 | 0.06 | 0.09 | 0.18 | |
| Capex to revenue | -0.02 | -0.03 | -0.03 | -0.03 | -0.06 | |
| Capex to depreciation | -0.38 | -0.66 | -0.74 | -0.75 | -1.46 | |
| Stock based compensation to revenue | 0.09 | 0.1 | 0.09 | 0.09 | 0.1 | |
| Graham number | 0.13 | 3.13 | 2.57 | 2.63 | 2.56 | |
| ROIC | -0.38 | 0.1 | 0.17 | 0.18 | 0.26 | |
| Return on tangible assets | -0.11 | -0.09 | -0.07 | -0.09 | -0.11 | |
| Graham Net | -1.05 | 0.89 | 0.67 | 0.47 | 0.27 | |
| Working capital | 39.02M | 100.21M | 94.55M | 88.04M | 82.3M | |
| Tangible asset value | -10.2M | 51.55M | 45.72M | 39.16M | 33.66M | |
| Net current asset value | -17.26M | 44.41M | 38.52M | 31.82M | 25.06M | |
| Invested capital | -607.49 | 0.87 | 0.98 | 1.12 | 1.28 | |
| Average receivables | 10.77M | 10.18M | 10.57M | 11.79M | 12.71M | |
| Average payables | 5.21M | 4.55M | 5.49M | 6.79M | 6.97M | |
| Average inventory | 11.08M | 11.64M | 12.61M | 13.99M | 15.71M | |
| Days sales outstanding | 56.64 | 56.09 | 59.77 | 58.36 | 59.31 | |
| Days payables outstanding | 57 | 58.36 | 78.97 | 77.38 | 68.97 | |
| Days of inventory on hand | 142.97 | 152.35 | 163.62 | 158.83 | 170.08 | |
| Receivables turnover | 1.59 | 1.6 | 1.51 | 1.54 | 1.52 | |
| Payables turnover | 1.58 | 1.54 | 1.14 | 1.16 | 1.3 | |
| Inventory turnover | 0.63 | 0.59 | 0.55 | 0.57 | 0.53 | |
| ROE | 72.36 | -0.17 | -0.15 | -0.22 | -0.27 | |
| Capex per share | -0.01 | -0.01 | -0.01 | -0.01 | -0.03 |
APEN Frequently Asked Questions
What is Apollo Endosurgery, Inc. stock symbol ?
Apollo Endosurgery, Inc. is a US stock , located in Austin of Tx and trading under the symbol APEN
Is Apollo Endosurgery, Inc. buy or a sell ?
2 stock analysts have 2 predictions with a medium analyst target price of $9.5. The lowest prediction is $9 and the highest is $10
What is APEN stock prediction ?
With a median analyst target price of $10, 1 stock analysts have made 1 forecasts in last 90 days. $10 is the lowest and $10 is the greatest projection.
What is Apollo Endosurgery, Inc. stock quote today ?
Apollo Endosurgery, Inc. stock price is $9.93 today.
Is Apollo Endosurgery, Inc. stock public?
Yes, Apollo Endosurgery, Inc. is a publicly traded company.
Company Profile
- Volume Average 1.41M
- Market Capitalization 469.79M
- Employee 202
- CEO Mr. Charles S. McKhann
- Headquarters Austin,TX,US
- IPO Date 2005-04-21
-
Website
https://www.apolloendo.com 
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, as well as delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands. Additionally, the company offers X-Tack Endoscopic HeliX Tacking System, a suture-based device for closing and healing defects in the lower and upper gastrointestinal tract. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Australia, Costa Rica, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.
